Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Equity Average (2016 - 2026)

Dexcom has reported Equity Average over the past 16 years, most recently at $2.9 billion for Q1 2026.

  • Quarterly Equity Average rose 30.53% to $2.9 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Mar 2026, up 30.53% year-over-year, with the annual reading at $2.4 billion for FY2025, 16.24% up from the prior year.
  • Equity Average was $2.9 billion for Q1 2026 at Dexcom, up from $2.7 billion in the prior quarter.
  • Over five years, Equity Average peaked at $2.9 billion in Q1 2026 and troughed at $2.0 billion in Q4 2022.
  • The 5-year median for Equity Average is $2.2 billion (2023), against an average of $2.3 billion.
  • Year-over-year, Equity Average fell 5.88% in 2024 and then skyrocketed 34.07% in 2025.
  • A 5-year view of Equity Average shows it stood at $2.0 billion in 2022, then grew by 9.61% to $2.2 billion in 2023, then fell by 5.88% to $2.0 billion in 2024, then surged by 34.07% to $2.7 billion in 2025, then rose by 4.22% to $2.9 billion in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Equity Average are $2.9 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.6 billion (Q3 2025).